Drug Trial Radar · NCT03519711
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia
Last checked: Nov 20, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 3, 2019
Primary completion
Oct 2, 2020
Study completion Oct 2, 2020
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to demonstrate the safety, pharmacokinetics (PK) and preliminary efficacy of PTC923 (CNSA-001) in reducing blood phenylalanine concentrations in participants with hyperphenylalaninemia due to primary BH4 deficiency (PBD).
Conditions
- BH4 Deficiency
- Hyperphenylalaninemia
Interventions
PTC923Drug
PTC923 will be administered per dose and schedule specified in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug (Day 1) up to 30 (±3) days after last dose of study drug (up to 50 days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Minnesota
Minneapolis, Minnesota
UT Southwestern
Dallas, Texas
University of Utah Hospital
Salt Lake City, Utah
Marshfield Clinic
Marshfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.